Search
Lung Cancer Clinical Trials in Stanford, CA
A listing of 15 Lung Cancer clinical trials in Stanford, CA actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 15
The city of Stanford, California, currently has 15 active clinical trials seeking participants for Lung Cancer research studies.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Featured Trial
Chronic Cough Clinical Study
Recruiting
We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required.
Conditions:
Cough
Chronic Cough
Asthma
Allergic Asthma
Sinusitis
Featured Trial
Non-Small Cell Lung Cancer Treatment
Recruiting
A Trial to Evaluate DZD9008 as a Treatment for People with Non-Small Cell Lung Cancer with EGFR Gene Mutations
Conditions:
NSCLC
Lung Cancer
Non-Small Cell Lung Cancer
Carcinoma
Non-Small-Cell Lung
Featured Trial
RSV Vaccine For Adults With Kidney, Liver or Lung Transplant
Recruiting
The RSVoice Trial is a Phase 3 clinical trial conducted by Moderna to evaluate the safety and immune response of an investigational vaccine aimed at preventing respiratory syncytial virus (RSV) infection in adults who have received a kidney, liver, or lung transplant.
Conditions:
Kidney Transplantation
Kidney Transplant
Liver Transplantation
Lung Transplantation
Chronic Kidney Disease
Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
Recruiting
The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor an... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Stanford University School of Medicine, Stanford, California
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Recruiting
In this study circulating tumor DNA (ctDNA) blood testing is used to detect the residual blood cancer. If residual cancer using this blood test is detected there may be at higher risk of having the cancer return. The study is going to test whether or not the number of circulating cancer cells detected in the blood can be reduced by administration durvalumab after the standard treatment if you are tested positive for the residual cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Stanford University, Stanford, California
Conditions: Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III
Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors
Recruiting
This study is to evaluate the safety, tolerability, and PK profiles of RMC-6291 and RMC-6236 in adults with KRAS G12C-mutated solid tumors.
Gender:
All
Ages:
Between 18 years and 125 years
Trial Updated:
06/13/2024
Locations: Stanford Cancer Institute, Stanford, California
Conditions: Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
A Study to Investigate LYL845 in Adults With Solid Tumors
Recruiting
This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2024
Locations: Stanford University, Stanford, California
Conditions: Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Recruiting
This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: Stanford Cancer Institute, Stanford, California
Conditions: Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer, Metastatic Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Recruiting
The goal of this study is to test A2B694, an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express MSLN and have lost HLA-A*02 expression.
The main questions this study aims to answer are:
Phase 1: What is the recommended dose of A2B694 that is safe for patients
Phase 2: Does the recommended dos... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Stanford University, Stanford, California
Conditions: Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer, NSCLC, Recurrent, Non-Small Cell Squamous Lung Cancer, Pancreas Cancer, Pancreatic Neoplasm, Colorectal Adenocarcinoma, CRC, Colon Cancer, Rectal Cancer, Cancer, Ovarian Cancer, Ovarian Neoplasms, Mesothelioma, Mesothelioma, Malignant, Ovary Cancer, Lung Cancer, MESOM
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: Stanford Cancer Center, Stanford, California
Conditions: Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
Recruiting
This study will consist of a Phase 1b and Phase 2 portion. The Phase 1b portion will enroll first followed by the Phase 2 portion. Each cycle of treatment = 28 days.
Subjects will receive alectinib twice daily. Those in the Phase 1b portion will receive alectinib alone. Those in Phase 2 Arm A will receive alectinib alone. Those in Phase 2, Arm B will receive SRS + alectinib.
A maximum of 25 cycles (2 years) of alectinib may be administered on study.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Stanford University, Stanford, California
Biodistribution&Pharmacokinetic of Position Emission Tomography(PET) Radiopharmaceutical 18F C SNAT4
Recruiting
Primary Objectives
Determine the biodistribution of [18F]-C-SNAT4 in 5 healthy volunteers. Secondary Objectives
Determine the dosimetry of [18F]-C-SNAT4 PET in healthy volunteers and patients with lung cancer.
Determine the acute toxicity of [18F]-C-SNAT4 PET in healthy volunteers and patients with lung cancer.
Determine whether uptake in [18F]-C-SNAT4 PET imaging is significantly different in tumor and corresponding contralateral noncancer tissue in patients with lung cancer (tested by Wilcoxo... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Stanford University, Stanford, California
Conditions: Cancer, Lung Cancer
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Recruiting
The purpose of this study is to test whether or not number of circulating cancer cells detected in the blood can be decreased the by combining the standard treatment (durvalumab) with Tremelimumab and additional chemotherapy
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Stanford University, Stanford, California
Conditions: Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Recruiting
A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: Stanford University Medical Center, Stanford, California
Conditions: HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Non-Small Cell Lung Cancer, HER2-positive Colorectal Cancer, HER2-positive Tumors, HER2 Low Breast Cancer
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
Recruiting
The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), and other solid tumors that express CEA and have lost HLA-A*02 expression.
The main questions this study aims to answer are:
Phase 1: What is the maximum or recommended dose of A2B530 that is safe for patients
Phase 2: Does the recommended dose of A2B530 kill the solid tumor cel... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/07/2024
Locations: Stanford University, Stanford, California
Conditions: Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms, Pancreas Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent, Non-Small Cell Squamous Lung Cancer, NSCLC, NSCLC, Recurrent, Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, CRC, Colorectal Cancer Metastatic, Cancer
1 - 12 of 15